Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study

Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study

Purpose: The purpose of this study was to examine the pharmacokinetics (PK), bioequivalence and safety of generic sunitinib and its original product Sutent® in healthy Chinese subjects through a phase-I clinical trial.Methods: The study selected two groups of 24 healthy Chinese subjects in a 1:1 rat...

Full description

Bibliographic Details
Main Authors: Yanli Wang, Qiaohuan Deng, Zhenyue Gao, Guangwen Liu, Zhengjie Su, Yicheng Zhao, Lixiu Zhang, Haimiao Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Pharmacology
Subjects:
bioequivalence
pharmacokinetics
renal cell carcinoma
sunitinib
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1294688/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1294688/full

Similar Items